Scientific publications
Marie Claire Tchamadeu
Other affiliations: Université Toulouse III - Paul Sabatier · Inserm
Paul Désiré Djomeni Dzeufiet
Pièrre Kamtchouing
Nelly Blaes
Other affiliations: Inserm · Institut des Maladies Métaboliques et Cardiovasculaires
Jean‐Pierre Girolami
Other affiliations: Inserm · Institut des Maladies Métaboliques et Cardiovasculaires
Pharmacognosy Research
AIM OF THE STUDY: Taub in normal and diabetic rats. MATERIALS AND METHODS: at various doses (38-300 mg/kg) in a single administration. In addition, STZ-induced diabetic rats received prolonged daily administration for 14 days. Glibenclamide (GB) (10 mg/kg) was used as reference treatment. In acute test, fasting blood glucose was followed for 5 h. In subacute test, body weight, food and water intakes, and blood glucose were followed weekly and serum biochemical parameters evaluated after 14 days treatment. RESULTS: < 0.01) reduced weight loss, and diabetes increased serum triglycerides, total cholesterol, and transaminases (alanine aminotransferase/aspartate aminotransferase) elevations. CONCLUSION: Taub stem bark extracts have possible value for antidiabetic oral medication. SUMMARY: : CH2Cl2/CH3OH: Dichloromethane/Methanol; STZ: Streptozotocin; GB: Glibenclamide; AE: Aqueous extract; OE: Organic extract; FeCl3: Iron (III) chloride; NaCl: Sodium chloride; K3Fe(CN)6: Potassium ferricyanide; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; H: Hour; BW: Body weight, W1 and W2: Weeks 1 and 2; CHOD: Cholesterol oxidase; GPO: Glycerol-3 Phosphate oxidase; PAP: Phenol + Aminophenazone.
